Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating Costs and Expenses:
General and administrative	$ 1,098,000	$ 1,474,000	$ 3,297,000	$ 4,525,000
Research and development	4,144,000	2,846,000	9,156,000	9,788,000
Total Operating Costs and Expenses	5,242,000	4,320,000	12,453,000	14,313,000
Loss from Operations	(5,242,000)	(4,320,000)	(12,453,000)	(14,313,000)
Other Income :
Change in fair value of warrant liability	0	626,000	0	4,064,000
Interest income	92,000	5,000	217,000	20,000
Total Other Income	92,000	631,000	217,000	4,084,000
Net Loss	(5,150,000)	(3,689,000)	(12,236,000)	(10,229,000)
Net Loss Attributable to Non-controlling Interest	(30,000)	(9,000)	(73,000)	(35,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(5,120,000)	(3,680,000)	(12,163,000)	(10,194,000)
Net Loss Attributable to Common Stockholders	$ (5,253,000)	$ (3,741,000)	$ (12,934,000)	$ (10,375,000)
Net Loss Per Share - Basic and Dilutive	$ (0.31)	$ (0.93)	$ (0.79)	$ (2.73)
Weighted average number of shares outstanding during the period - Basic and Dilutive	16,805,257	4,028,304	16,313,326	3,802,812
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (63,000)	$ (61,000)	$ (185,000)	$ (181,000)
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0
Preferred Stock Dividends, Income Statement Impact	$ (70,000)	$ 0	$ (585,000)	$ 0